PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 6, 2024Endocrine Abstracts0 citations

Using a SGLT2 inhibitor does not modify the efficacy and tolerability of extended-release metformin in patients with type 2 diabetes

View Full Paper
BSBorja Santana-OjedaAHAlba Hernández-LázaroDJde Leon-Durango Ricardo Jose

Key Points

Key points are not available for this paper at this time.

Abstract

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Santana-Ojeda et al. (2024) studied this question.

synapsesocial.com/papers/68e6b6e1b6db6435876382dahttps://doi.org/10.1530/endoabs.99.ep1268
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Metabolic and cardio-renal benefits of SGLT2- inhibitors in diabetic patients2024
  2. 2The effect of SGLT-2 inhibitor switching from TZD with triple combination treatment in type 2 diabetes2024
  3. 3Improvement in albumin excretion in patients with type 2 diabetes mellitus labelled as metformin-intolerant after rechallenge with extender-release metformin2024
  4. 4Rechallenge with extended-release metformin in patients with type 2 diabetes labelled as metformin-intolerant: satisfaction and its determinants2024
  5. 5Changes in lipid profile in patients with type 2 diabetes labeled as metformin-intolerant rechallenged with extended release metformin2024